-
Join 674 other subscribers
-
Recent Posts
- Board IPR decisions finding conception and reduction to practice before critical date affirmed
- SCOTUS concludes Amgen’s anti-PCSK9 antibody claims not enabled
- Board IPR claim construction (even with harmless error) and obviousness determination affirmed
- DC findings that Vanda’s method of treatment claims are invalid for obviousness affirmed
- IPR obviousness decision reversed as prior art not shown to be analogous to Sanofi’s claimed invention
Recent Comments
Categories
- America Invents Act
- Analgous Art
- Anticipation (35 USC 102)
- Antitrust
- Appeal
- Arbitration
- Article III disputes
- Assignment / Ownership
- Attorney's Fees
- Bankruptcy
- Best mode
- Biosimilars
- Business methods
- Certificate of Correction
- Claim
- Claim Construction
- Claim Differentiation
- Claim Preclusion
- Claim Vitiation
- Collateral estoppel
- comprising
- Conception and Reduction to Practice
- consisting of
- Contributory Infringement
- Copyright
- Covered Business Method Reviews
- Damages
- Derivation of Invention
- Design Patents
- Diligence
- Disclaimers
- Discovery
- Doctrine of equivalents
- Double Patenting
- Enablement
- Equitable estoppel
- Exhaustion and Repair
- Experimental Use
- Expert Testimony
- Extension (156)
- False Marking
- Functional limitations
- Generics / ANDA
- Importation
- Incorporation by Reference
- Indefiniteness
- Inducement to Infringe
- Inequitable Conduct
- Infringement
- Inherency
- Injunction
- Inter Parties Review (IPR)
- Interference
- International Trade Commission
- Intervening Rights
- Inventorship
- IPR
- Issue Preclusion
- Jurisdiction
- Laches
- Licensing
- Lost Profits
- Malpractice
- Markush
- Means-plus-function
- Medical Devices
- Method claims
- Negative Limitations
- Obviousness
- Obviousness (Secondary Considerations)
- Obviousness-Teaching Away
- On-Sale Bar
- Patent Eligibility (101)
- Patent Exhaustion
- Patent Marking
- Patent Prosecution
- Patent Term Adjustment (PTA)
- Patent Term Extension
- Patentability
- Post-grant review
- Preamble
- Priority
- Privilege
- Procedural Issues
- Product-by-Process
- Prosecution History Estoppel
- Public Accessibility
- Public Use
- Ranges
- Reexamination
- Reissue
- Royalties
- Safe Harbor, FDA exemptions (271(e)(1))
- Section 101 (see also Patentability)
- Software
- State Sovereignty
- Summary Judgment
- Terminal Disclaimers
- Trade Dress
- Trade Secret
- Trademarks
- U.S. Supreme Court
- Uncategorized
- Unenforceability
- Unjust enrichment
- Utility
- Venue
- Wherein
- Willfullness
- Written description
Archives
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- July 2011
- February 2011
- January 2011
Meta
- Anticipation (35 USC 102) Appeal Article III disputes Assignment / Ownership Attorney's Fees Claim Construction Claim Differentiation Damages Doctrine of equivalents Enablement Generics / ANDA Indefiniteness Inducement to Infringe Infringement Inter Parties Review (IPR) Inventorship IPR Licensing Means-plus-function Obviousness Obviousness-Teaching Away Patentability Patent Eligibility (101) Prosecution History Estoppel Reexamination Software Trademarks Uncategorized Willfullness Written description
Copyright Notice
© Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com, [2011-2017]. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Patrick J. Halloran, Ph.D., J.D. and lifescienceip.wordpress.com with appropriate and specific direction to the original content.
Category Archives: Inventorship
DC inventorship decision reversed as contribution “not significant when measured against the scope of the full invention”
Hip, Inc. v. Hormel Foods Corporation Docket No. 2022-1696 (https://cafc.uscourts.gov/opinions-orders/22-1696.OPINION.5-2-2023_2120058.pdf) LOURIE, CLEVENGER, TARANTO May 2, 2023 Brief Summary: DC decision finding party should have been name a joint inventor reversed as contribution “not significant when measured against the scope … Continue reading
Board IPR decision of no anticipation affirmed (untimely arguments, portions of prior art relied upon not “by another”)
LSI Corporation and Avago Techs. U.S. Inc. v. Regents of the University of Minnesota Docket No. 2021-2057 (IPR2017-01068) (https://cafc.uscourts.gov/opinions-orders/21-2057.OPINION.8-11-2022_1990664.pdf) DYK, REYNA, HUGHES August 11, 2022 Brief Summary: Board decision that LSI did not timely raise arguments or show portions … Continue reading
Artificial intelligence cannot be an inventor under the Patent Act, Fed. Cir. holds
Stephen Thaler v. Vidal/USPTO Docket No. 2021-2347 (https://cafc.uscourts.gov/opinions-orders/21-2347.OPINION.8-5-2022_1988142.pdf) MOORE, TARANTO, STARK August 5, 2022 Brief Summary: FC panel affirms ED VA and USPTO findings that only human beings and not computers (i.e., artificial intelligence) can be inventors under the … Continue reading
Posted in Inventorship
Leave a comment
DC reversed on WD of genus claims and patent co-ownership, affirmed on no willfulness and remanded for damages calculation
BASF Plant Science, L.P., Cargill, Inc. v. Commonwealth Scientific, et al. (“CSIRO”) Docket No. 2020-1415-16, 2020-1919-20 (https://cafc.uscourts.gov/opinions-orders/20-1415.OPINION.3-15-2022_1921729.pdf) NEWMNA (D), TARANTO, CHEN March 15, 2022 Brief Summary: Following a dispute regarding a collaboration agreement, FC panel affirmed DC fining on … Continue reading
DC finding that Horizon’s OB patents are obvious and/or not infringed affirmed
Horizon Medicines LLC v. Alkem Laboratories Ltd. Docket No. 2021-1480 (https://cafc.uscourts.gov/opinions-orders/21-1480.OPINION.11-16-2021_1865455.pdf) (Non-precedential) DYK, O’MALLEY, HUGHES November 16, 2021 Brief Summary: DC refusal to change inventorship, finding of obviousness and no infringement of Horizon’s patents affirmed. Summary: Horizon appealed DC finding … Continue reading
ITC findings that Bio-Rad infringed and does not co-own 10X patents affirmed
Bio-Rad Laboratories, Inc. v. International Trade Commission, 10X Genomics Inc. Docket No. 2020-1785 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1785.OPINION.4-29-2021_1770917.pdf) TARANTO, CHEN, STOLL April 29, 2021 Brief Summary: ITC infringement and no co-ownership findings affirmed. Summary: Bio-Rad appealed International Trade Commission (ITC) decision finding infringement and … Continue reading
DC claim construction affirmed; refusal to correct inventorship vacated/remanded (“AIA did not narrow the meaning of ‘error’”)
Egenera, Inc. v. Cisco Systems, Inc. Docket No. 2019-2015, -2387 PROST, REYNA, STOLL August 28, 2020 Brief Summary: DC claim construction affirmed; refusal to allow Egenera to correct inventorship vacated/remanded (“AIA did not narrow the meaning of ‘error’”). Summary: Egenera … Continue reading
DC decision adding Dana Farber/GI (Pfizer) inventors to Ono/BMS anti-PD1 patents affirmed
Dana-Farber Cancer Institute, Inc. v. Ono Pharm. Co., et al. (Bristol-Myers Squibb) Docket No. 2019-2050 NEWMAN, LOURIE, STOLL July 14, 2020 Brief Summary: DC order to add Dana Farber and GI/Pfizer inventors to the Ono/BMS relating to the use of … Continue reading
Dana-Farber and Genetic Institute researchers named co-inventors on the “Honjo patents” encompassing methods for treating cancer using anti-PD1 antibodies including BMS’s Opdivo® (nivolumab)
Dana-Farber Cancer Institute, Inc. v. Ono Pharmaceutical Co., Ltd. et al. Civil Action No. 15-13443-PBS U.S. District Court, District of Massachusetts May 17, 2019 Brief summary: DC determines Dana-Farber and Genetics Institute researchers to be co-inventors on the Honjo patents … Continue reading
Posted in Inventorship
Leave a comment
CODA Development S.R.O. et al. and Frantisek Hrabal (“Coda”) v. Goodyear Tire & Rubber Co., et al.
Docket No. 2018-1028 PROST, WALLACH, HUGHES February 22, 2019 Brief summary: DC dismissal of Coda’s complaint seeking correction of inventorship (§ 256) of several Goodyear patents and applications, and trade secret misappropriation claims as time barred, was vacated and remanded. … Continue reading
Posted in Inventorship, Trade Secret
Leave a comment